Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world

Cayman, Akadeum to revolutionize cell isolation for cell and gene therapy

Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio

Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr

BIL also holds an option to increase its equity stake by an additional 15%

DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs

The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.

Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer

Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab

Dr. Reddy's receives positive CHMP opinion from EMA for denosumab 'AVT03'

Prolia is a prescription medicine used to treat osteoporosis in women

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population

Merck & Siemens join forces to accelerate AI drug discovery and development

Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry